Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Seagen logo

About Seagen Stock (NASDAQ:SGEN)

Key Stats

Today's Range
$228.74
▼
$228.74
50-Day Range
$228.74
▼
$228.74
52-Week Range
$123.77
▼
$228.96
Volume
N/A
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGEN Stock News Headlines

Pfizer raises guidance as COVID franchise drives Q3 beat
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright.tc pixel
Franklin Biotechnology Discovery C
Pfizer: Turning The Corner (Rating Upgrade)
See More Headlines

SGEN Stock Analysis - Frequently Asked Questions

Seagen Inc. (NASDAQ:SGEN) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.33. Seagen's revenue for the quarter was up 27.1% on a year-over-year basis.

Seagen subsidiaries include Cascadian Therapeutics.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bristol Myers Squibb (BMY), Salesforce (CRM), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
11/01/2023
Today
10/26/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CIK
1060736
Employees
3,256
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($4.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$610.31 million
Net Margins
-32.61%
Pretax Margin
-32.12%
Return on Equity
-28.06%
Return on Assets
-20.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.67
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$2.30 billion
Price / Sales
18.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.10 per share
Price / Book
15.15

Miscellaneous

Outstanding Shares
187,698,000
Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
Optionable
Beta
0.32

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:SGEN) was last updated on 4/8/2026 by MarketBeat.com Staff.
From Our Partners